Biotechnology

Gilead Sciences

Gilead and Horizon Complete Acquisition of Ouro Medicines, Securing Global Rights for Gamgertamig

Gilead Sciences Chairman O'Day Sells 15k Shares for ~$1.97M

Gilead Announces Positive Phase 3 Results for Livdelzi in PBC Treatment

FDA Approves Gilead's Drug for Rare Chronic Hepatitis D Treatment

Gilead's Trodelvy Receives Positive CHMP Opinion for First-Line Treatment of TNBC

Gilead Completes Acquisition of Tubulis, Investing $3.15 Billion to Enhance Oncology Portfolio

Gilead Issues $3 Billion Senior Notes for General Corporate Purposes

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

WHO Procurement Mechanism Selects South African Lab to Produce AIDS Generic Drug

Analysts at Cantor Fitzgerald and Bernstein Give Buy Rating to Gilead Sciences

Gilead Sciences released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.96 B (forecast USD 6.929 B), actual EPS USD 1.61 (forecast USD 1.5805)

Gilead Sciences Raises 2026 Sales Forecast

Gilead Sciences reports Q1 product sales of $6.946 billion

WealthShield Partners LLC builds new position and increases holdings in Gilead Sciences

Gilead's HIV Prevention Shot Yeztugo Prescriptions Increase But Face Insurance Limitations

GC Wealth Management RIA LLC Reduces Holdings in Gilead Sciences

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

Ordinary dividend (cash)

Ex Date: 2026.06.15 (EST), Cash dividend 0.82 USD

Gilead Sciences, Inc. (GILD.US) Q4 2025 Earnings Conference Call

Gilead Sciences, Inc. (GILD.US) Q1 2025 Earnings Conference Call

Gilead Sciences, Inc. (GILD.US) Q4 2024 Earnings Conference Call

Gilead Sciences, Inc. (GILD.US) Q3 2024 Earnings Conference Call

GILD

Gilead Sciences (GILD) shares fell 2.03% to $125.50 on Tuesday, marking its third consecutive day of losses and underperforming competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories. The stock remains 20.21% below its 52-week high. Trading volume reached 8.6 million, exceeding the 50-day average.

MarketWatch Automated

Gilead Sciences, Inc.

Dow Jones Industrial Average

S&P 500

Johnson & Johnson

Pfizer

Abbott Laboratories

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Gilead and Merck discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial for Trodelvy plus Keytruda in lung cancer due to lack of statistical significance in progression-free survival. Separately, they reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met primary efficacy endpoints. Regulatory filings are planned for the HIV treatment.

benzinga_article

Merck

Terns Pharmaceuticals

Shutterstock

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

PGEN

RBC Capital Markets warns Gilead Sciences faces a potential threat from in vivo CAR-T technology, which could impact 10-15% of its future revenue. While Gilead's ex vivo franchise is expected to grow, reaching over $4 billion by decade-end, in vivo therapy offers a broader patient eligibility alternative. RBC maintains a sector perform rating with a $122 price target, noting Gilead's acquisitions of Interius and collaboration with Pregene to integrate in vivo platforms.

Fidelity

Precigen

ROYAL BANK OF CANADA

Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says

Gilead Sciences and Merck announced positive topline results from two Phase 3 trials (ISLEND-1 and ISLEND-2) evaluating islatravir/lenacapavir, an investigational once-weekly oral HIV treatment. Both studies met their primary efficacy endpoints at Week 48, demonstrating that the regimen was statistically non-inferior to current standard-of-care therapies. The safety profile was comparable to comparators, with no new safety concerns identified. The companies plan to submit global regulatory filings for this potential first long-acting oral HIV therapy.

StockTitan

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment | MRK Stock News

Merck and Gilead Sciences announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study. The trial investigated Trodelvy combined with KEYTRUDA versus KEYTRUDA monotherapy for untreated metastatic non-small cell lung cancer. An external Data Monitoring Committee recommended stopping the study after pre-specified analyses showed no statistically significant improvement in progression-free survival and an unlikely probability of achieving statistical significance in overall survival.

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study | MRK Stock News

BI Asset Management reduced its Gilead Sciences stake by 5.1% in Q4, holding 453,467 shares valued at $55.7 million. Other institutions like Ares and Financial Consulate also adjusted positions. Analysts maintain a 'Moderate Buy' consensus with an average price target of $156.93. Insiders Johanna Mercier and Andrew Dickinson sold shares in mid-May under pre-arranged plans.

Market Beat

Jefferies Financial

Truist Financial

Bank of America

Oppenheimer

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Gilead Sciences, Inc. $GILD Shares Sold by BI Asset Management Fondsmaeglerselskab A S

ASMB

Assembly Biosciences (ASMB) is advancing its liver disease pipeline, specifically ABI-6250, into hepatitis delta and cholestatic indications like PBC and PSC. CEO Jason Okazaki noted positive Phase 1a data and plans for Phase 2 trials starting late this year. Meanwhile, the company awaits Gilead Sciences' development plan for HSV programs, with a decision on U.S. cost-sharing expected mid-year.

Assembly Biosciences

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines for $1.675 billion plus up to $500 million in milestones. The deal grants Gilead commercialization rights for Gamgertamig, a T-cell engager for autoimmune diseases, while Lakefront retains development responsibilities and royalty income. This transaction also resolves a prior licensing agreement, allowing Lakefront to acquire additional preclinical programs and boosting its cash reserves.

nasdaq

Lakefront Biotherapeutics

Nasdaq

Gilead And Lakefront Acquire Ouro Medicines In $1.67 Bln Agreement; To Co-Develop Gamgertamig

Gilead Sciences(GILD.US)